✦ LIBER ✦

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma

✍ Scribed by Paul V. Woolley; Carolyn J. Schultz; Gladys I. Rodriguez; Richard A. Gams; Kenneth W. Rowe; Mary Lee Dadey; Daniel D. Hoff; Joseph J. McPhillips

Publisher: Springer US
Year: 1996
Tongue: English
Weight: 300 KB
Volume: 14
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00210794

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 4′ deoxydoxorubicin (D

Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma

✍ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response

Phase II trial of trimetrexate for unres

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

✍ Frank V. Fossella; Rodger J. Winn; Paul Y. Holoye; Becky Hallinan; Martin N. Rab 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 368 KB

Phase II trial of intravenous 6-thioguan

Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma

✍ Frank V. Fossella; Rodger J. Winn; Paul Y. Holoye; Martin N. Raber; Larry Holden 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 132 KB

Failure of the perioperative PCV neoadju

Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma results from a randomized phase II trial

✍ Bertrand Dautzenberg; Jacques Benichou; Philippe Allard; Bernard Lebeau; Daniel 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 673 KB

Benefits of polychemotherapy in advanced

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma

✍ Yvon Cormier; Dollard Bergeron; Jacques La Forge; Michel Lavandier; Marcien Four 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 2 views

The benefits of polychemotherapy in advanced (Stage 111) non-small-cell bronchogenic carcinoma remain uncertain. In attempt to answer the important question whether treatment improves well-being and survival in these patients, we did a prospective, randomized, single-blind study to compare polychemo

Phase II study of tiazofurin (NSC 286193

Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma

✍ Paul Y. Holoye; David T. Carr; Hari M. Dhingra; Bonnie S. Glisson; Jin S. Lee; W 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 115 KB

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderat